- Fellowship - University of Texas Health Science Center, San Antonio (1984-1988), Hematology Oncology
- Medical School - Universidad de Guayaquil, Ecuador (1972-1980)
- Residency - Emory University School of Medicine (1981-1984), Internal Medicine
Carlos Arteaga, M.D.
- The Lisa K. Simmons Distinguished Chair in Comprehensive Oncology
- Internal Medicine - Hematology/Oncology
- Advanced, Inflammatory, Metastatic or Recurrent Breast Cancers
- Breast Cancers
Dr. Carlos L. Arteaga is the Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs at UT Southwestern Medical Center.
Dr. Arteaga earned his medical degree at the University of Guayaquil in Ecuador. He trained in internal medicine and medical oncology at Emory University and the University of Texas Health Science Center at San Antonio. He joined Vanderbilt University Medical Center in 1989, where he held the Donna S. Hall Chair in Breast Cancer Research and served at the Vanderbilt-Ingram Cancer Center (VICC) as Director of the Center for Cancer Targeted Therapies, the Director of the Breast Cancer Program, and the Associate Director for Translational/Clinical Research until 2017, when he joined UT Southwestern.
Dr. Arteaga has more than 300 publications in the areas of oncogenes and breast tumor initiation and progression, development of targeted therapies and biomarkers of drug action and resistance, and investigator-initiated clinical trials in breast cancer. His research is or has been funded by the National Cancer Institute (NCI), CPRIT, the American Cancer Society, the Department of Defense Breast Cancer Research Program, Stand Up 2 Cancer (SU2C), and the Susan G. Komen for the Cure and Breast Cancer Research foundations.
During his career, Dr. Arteaga has received several awards, including the American Association for Cancer Research-Richard and Hinda Rosenthal Award, the American Cancer Society Clinical Research Professor Award, the Gianni Bonadonna Award from the American Society of Clinical Oncology, the Brinker Award for Scientific Distinction from the Susan G. Komen Foundation, the 2015 Prize for Scientific Excellence in Medicine from the American-Italian Cancer Foundation, and the Clinical Investigator Award from the U.S. Department of Veteran Affairs.
He is an elected Fellow of the American Association for the Advancement of Science, a Fellow of the American Association for Cancer Research Academy, an elected member of both the American Society for Clinical Investigation and the Association of American Physicians, and member of the Susan G. Komen Scientific Advisory Board. He also serves on the advisory boards of several academic Breast Cancer Programs and NCI-designated Cancer Centers.
Meet Dr. Arteaga
World renowned breast cancer specialist and investigator
As one of the country’s leading physician scientists in the treatment and research of breast cancer, and with almost three decades of clinical experience, Carlos L. Arteaga, M.D., likes to talk about the good news he has for his patients.
“The treatment of breast cancer has evolved dramatically over the last 30 years,” he says. “As cancer care has become increasingly sophisticated, the mortality for breast cancer has been increasingly in decline.”
Dr. Arteaga joined UT Southwestern in 2017 to take the helm as Director of the Harold C. Simmons Comprehensive Cancer Center and Associate Dean of Oncology Programs. He sees his position as the best way to continue his work in the remaking of cancer from a death sentence to a fallible foe.
Early Interventions Drive Optimal Outcomes
Dr. Arteaga points to a few things that have been key to the turning tides of breast cancer survival.
“A main reason has been the wide use of screening mammograms, which allow detection of cancers when they are small and contained in the breast – and thus with high chances of cure. In addition, research and drug development have markedly improved treatments across all three breast cancer subtypes,” he says.
Early detection has had a huge impact in breast cancer outcomes. “If you go back 30 years,” Dr. Arteaga says, “probably 30 percent of breast cancers were diagnosed at stage 4 – when they are disseminated throughout the body and more difficult to cure. Today, however, women who are diagnosed at stage 4 breast cancer are a distinct minority.”
In fact, today many breast cancers are detected so early that a woman needs only limited surgery and adjuvant therapy in order to expect a full recovery.
Dr. Arteaga says that breast cancer care has also improved because of today’s multidisciplinary approach to treatment.
“At UT Southwestern and other top cancer centers, a woman who receives a breast cancer diagnosis sees different breast specialists on day one. She might see a breast medical oncologist and a breast surgeon. And she might see other experts as well, such as a radiation oncologist, a plastic surgeon, and a genetic counselor.”
Dr. Arteaga says this collaborative approach to care at the time of cancer diagnosis significantly improves a woman’s outcomes.
The Rewards of Research
Another reason that breast cancer treatment has made so much progress is the abundance of new drugs and rational combinations being tested in clinical trials, which are the mechanism that allows physician scientists, such as Dr. Arteaga, and clinical investigators translate laboratory discoveries into approved therapies.
“Clinical trials are the only instrument we have as physicians and investigators to get new and better drugs approved,” he says.
Dr. Arteaga offers his patients the opportunity to participate in clinical trials whenever possible.
“A patient who is in a clinical trial is really getting the most superior care available,” he says. “These patients are being followed very closely, not only by a group of physicians but also by a team of nurses and other highly skilled providers.”
“By participating in clinical trials, our patients are a key part of the cancer research enterprise,” he says. “They have a perspective that we don't have as investigators. We cannot do it without them. They're an invaluable part of how we move forward.”
Pushing the Leading Edge
Dr. Arteaga is eager to see how clinical research will continue to improve cancer care in the next 10 years. “But there are still many other issues that we have to face,” he notes.
“It's not all about the next best technology or treatment. We also have to keep in mind that there are issues with disparities of care and screening that are important. And those are things that UT Southwestern has addressed and will continue to address.”
Still too many patients die from cancer and we should honor them with renewed commitment to continue our efforts to reduce cancer mortality, Dr. Arteaga says. But there is every reason to have an optimistic outlook.
“We've made enormous progress,” he says. “I think that we live in an unprecedented time in the history of cancer care and cancer research. The momentum has never been greater. And I think the next 10 years are going to be transformative in the way we think of cancer, in the way we understand cancer, and in the way we go about treating it. It's going to be close to unimaginable.”
Neratinib: Inching up on the cure rate of HER2+ breast cancer?
Unni N, Sudhan DR, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2018 May
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors.
Guerrero-Zotano A, Stricker T, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Pérez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, Andre F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2018 Mar
Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer?
Garrett JT, Chakrabarty A, Arteaga CLOncotarget 2018 Aug 9 64 32400
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy JAnnals of oncology : official journal of the European Society for Medical Oncology 2018 Apr
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JMOncoimmunology 2018 7 6 e1438106
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CLJournal of the National Cancer Institute 2017 Nov 109 11
An Acquired HER2(T798I) Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.
Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CLCancer discovery 2017 Jun 7 6 575-585
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiello-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone MThe Lancet. Oncology 2017 Jul 18 7 904-916
PIK3CA C2 domain deletions hyperactivate phosphoinositide 3-kinase (PI3K), generate oncogene dependence and are exquisitely sensitive to PI3Ka inhibitors.
Croessmann S, Sheehan JH, Lee KM, Sliwoski GR, He J, Nagy RJ, Riddle DA, Mayer IA, Balko JM, Lanman RB, Miller V, Cantley LC, Meiler J, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2017 Dec
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanovic B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JAClinical cancer research : an official journal of the American Association for Cancer Research 2017 Aug 23 15 4035-4045
Is There a Future for AKT Inhibitors in the Treatment of Cancer?
Jansen VM, Mayer IA, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2016 Jun 22 11 2599-601
Drug response in organoids generated from frozen primary tumor tissues.
Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MCScientific reports 2016 Jan 6 18889
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
Guerrero-Zotano A, Mayer IA, Arteaga CLCancer metastasis reviews 2016 Dec 35 4 515-524
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy JThe New England journal of medicine 2016 11 375 18 1738-1748
The PI3K/AKT Pathway as a Target for Cancer Treatment.
Mayer IA, Arteaga CLAnnual review of medicine 2016 67 11-28
Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy.
Stricker T, Arteaga CLCancer discovery 2015 Nov 5 11 1124-6
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers.
Young CD, Arteaga CL, Cook RSBreast cancer research : BCR 2015 Dec 17 148
PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer?
Mayer IA, Arteaga CLJournal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Sep 32 27 2932-4
AACR Cancer Progress Report 2014.
Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, Limburg PJ, Lowe SW, Mardis ER, Ramsey S, Rebbeck TR, Richardson AL, Rubin EH, Weiner GJClinical cancer research : an official journal of the American Association for Cancer Research 2014 Oct 20 19 Suppl S1-S112
Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CLBreast cancer research : BCR 2014 Jan 16 1 R9
Heart failure and breast cancer therapies: moving towards personalized risk assessment.
Francis SA, Cheng S, Arteaga CL, Moslehi JJournal of the American Heart Association 2014 Feb 3 1 e000780
Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CLCancer discovery 2014 Feb 4 2 232-45
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JABreast cancer research : BCR 2014 Aug 16 4 406
Emergence of constitutively active estrogen receptor-a mutations in pretreated advanced estrogen receptor-positive breast cancer.
Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VAClinical cancer research : an official journal of the American Association for Cancer Research 2014 Apr 20 7 1757-1767
Mouse models and anti-HER2 therapies.
Hanker AB, Cook RS, Arteaga CLOncotarget 2013 Nov 4 11 1866-7
Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy.
Rexer BN, Shyr Y, Arteaga CLJournal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Jun 31 17 2073-5
Optimal targeting of HER2-PI3K signaling in breast cancer: mechanistic insights and clinical implications.
Rexer BN, Arteaga CLCancer research 2013 Jul 73 13 3817-20
Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program.
Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, Hong CC, Shirey-Rice JK, Arteaga CL, Mayer IA, Holroyd KJ, Cook RSTargeted oncology 2017 Dec
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CLThe Journal of clinical investigation 2014 Dec 124 12 5490-502
Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer.
Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GBClinical cancer research : an official journal of the American Association for Cancer Research 2013 Jul 19 13 3703-13
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.
Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2013 Feb 19 3 610-9
mutations and ER results in synthetic lethality of ER+/HER2 mutant breast cancer.
Croessmann S, Formisano L, Kinch L, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin N, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2018 Oct
TGF-ß signaling promotes tumor vasculature by enhancing the pericyte-endothelium association.
Zonneville J, Safina A, Truskinovsky AM, Arteaga CL, Bakin AVBMC cancer 2018 Jun 18 1 670
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
O'Shaughnessy J, Petrakova K, Sonke GS, Conte P, Arteaga CL, Cameron DA, Hart LL, Villanueva C, Jakobsen E, Beck JT, Lindquist D, Souami F, Mondal S, Germa C, Hortobagyi GNBreast cancer research and treatment 2017 Nov
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2(+) Breast Cancer.
Hanker AB, Estrada MV, Bianchini G, Moore PD, Zhao J, Cheng F, Koch JP, Gianni L, Tyson DR, Sánchez V, Rexer BN, Sanders ME, Zhao Z, Stricker TP, Arteaga CLCancer research 2017 Jun 77 12 3280-3292
(18)F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.
Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GAClinical cancer research : an official journal of the American Association for Cancer Research 2017 Jun 23 12 3053-3060
Association of FGFR1 with ERamaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer.
Formisano L, Stauffer KM, Young CD, Bhola NE, Guerrero-Zotano AL, Jansen VM, Estrada MM, Hutchinson KE, Giltnane JM, Schwarz LJ, Lu Y, Balko JM, Deas O, Cairo S, Judde JG, Mayer IA, Sanders M, Dugger TC, Bianco R, Stricker T, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2017 Jul
Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors.
Abramson VG, Supko JG, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, Shapiro GI, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2017 Jul 23 14 3520-3528
A Phase Ib Study of Alpelisib (BYL719), a PI3Ka-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA, Abramson VG, Formisano L, Balko JM, Estrada MV, Sanders ME, Juric D, Solit D, Berger MF, Won HH, Li Y, Cantley LC, Winer E, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2017 Jan 23 1 26-34
HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2.
Hanker AB, Garrett JT, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford E, Owens P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Majjaj S, Brohée S, Venet D, Brown D, Baselga J, Piccart M, Sotiriou C, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2017 Aug 23 15 4323-4334
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JMClinical cancer research : an official journal of the American Association for Cancer Research 2016 Mar 22 6 1499-509
Systematic Prioritization of Druggable Mutations in ~5000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach.
Zhao J, Cheng F, Wang Y, Arteaga CL, Zhao ZMolecular & cellular proteomics : MCP 2016 Feb 15 2 642-56
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CLScience translational medicine 2016 Apr 8 334 334ra53
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
Dillon LM, Bean JR, Yang W, Shee K, Symonds LK, Balko JM, McDonald WH, Liu S, Gonzalez-Angulo AM, Mills GB, Arteaga CL, Miller TWOncogene 2015 Jul 34 30 3968-76
Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.
Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MCCancer research 2014 Sep 74 18 5184-94
In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.
McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MCBiomedical optics express 2014 Jul 5 7 2247-61
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Mayer IA, Abramson VG, Isakoff SJ, Forero A, Balko JM, Kuba MG, Sanders ME, Yap JT, Van den Abbeele AD, Li Y, Cantley LC, Winer E, Arteaga CLJournal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Apr 32 12 1202-9
Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response.
Rexer BN, Arteaga CLBreast cancer research : BCR 2014 16 2 303
Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.
Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MCCancer research 2013 Oct 73 20 6164-74
ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, Cook RSThe Journal of clinical investigation 2013 Oct 123 10 4329-43
TGF-ß inhibition enhances chemotherapy action against triple-negative breast cancer.
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CLThe Journal of clinical investigation 2013 Mar 123 3 1348-58
Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CLCancer research 2013 Jul 73 13 4075-85
Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors.
Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CLCancer research 2013 Feb 73 3 1190-200
Progress in breast cancer: overview.
Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2013 Dec 19 23 6353-9
Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CLProceedings of the National Academy of Sciences of the United States of America 2013 Aug 110 35 14372-7
Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial.
Sudhan DR, Schwarz LJ, Guerrero-Zotano A, Formisano L, Nixon MJ, Croessmann S, Gonzalez-Ericsson PI, Sanders M, Balko JM, Avogadri-Connors F, Cutler RE, Lalani AS, Bryce R, Auerbach A, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2018 Oct
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DBNature 2018 Feb 554 7691 189-194
The Attenuation Distribution Across the Long Axis of Breast Cancer Liver Metastases at CT: A Quantitative Biomarker for Predicting Overall Survival.
Abramson RG, Lakomkin N, Hainline A, Kang H, Hutson MS, Arteaga CLAJR. American journal of roentgenology 2017 Oct W1-W7
Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors.
Limoge M, Safina A, Truskinovsky AM, Aljahdali I, Zonneville J, Gruevski A, Arteaga CL, Bakin AVOncotarget 2017 Sep 8 37 61969-61981
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.
Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, Andrejeva G, Rathmell JC, Fesik SW, Arteaga CLCell metabolism 2017 Oct 26 4 633-647.e7
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Kodack DP, Askoxylakis V, Ferraro GB, Sheng Q, Badeaux M, Goel S, Qi X, Shankaraiah R, Cao ZA, Ramjiawan RR, Bezwada D, Patel B, Song Y, Costa C, Naxerova K, Wong CSF, Kloepper J, Das R, Tam A, Tanboon J, Duda DG, Miller CR, Siegel MB, Anders CK, Sanders M, Estrada MV, Schlegel R, Arteaga CL, Brachtel E, Huang A, Fukumura D, Engelman JA, Jain RKScience translational medicine 2017 May 9 391
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CLCancer research 2017 May 77 9 2488-2499
Inhibition of TGF-ß with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression.
Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, Moses HL, Freeman ML, Arteaga CLThe Journal of clinical investigation 2017 Mar 127 3 1116
Neoadjuvant Trials in ER(+) Breast Cancer: A Tool for Acceleration of Drug Development and Discovery.
Guerrero-Zotano AL, Arteaga CLCancer discovery 2017 Jun 7 6 561-574
Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, G?mez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CLScience translational medicine 2017 Aug 9 402
Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PEMolecular oncology 2017 Apr 11 4 405-421
PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJOncogene 2016 Jun 35 23 2961-70
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
Joseph JD, Darimont B, Zhou W, Arrazate A, Young A, Ingalla E, Walter K, Blake RA, Nonomiya J, Guan Z, Kategaya L, Govek SP, Lai AG, Kahraman M, Brigham D, Sensintaffar J, Lu N, Shao G, Qian J, Grillot K, Moon M, Prudente R, Bischoff E, Lee KJ, Bonnefous C, Douglas KL, Julien JD, Nagasawa JY, Aparicio A, Kaufman J, Haley B, Giltnane JM, Wertz IE, Lackner MR, Nannini MA, Sampath D, Schwarz L, Manning HC, Tantawy MN, Arteaga CL, Heyman RA, Rix PJ, Friedman L, Smith ND, Metcalfe C, Hager JHeLife 2016 Jul 5
Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, Grandis JR, Arteaga CLCancer research 2016 Jan 76 2 440-52
Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA (H1047R) in HER2/ER-positive breast cancer.
Cheng F, Zhao J, Hanker AB, Brewer MR, Arteaga CL, Zhao ZBreast cancer research and treatment 2016 Dec 160 3 457-474
In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.
Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak KNature genetics 2015 Oct 47 10 1212-9
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BHProceedings of the National Academy of Sciences of the United States of America 2015 Nov 112 45 E6205-14
NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys.
Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FMJournal of the National Comprehensive Cancer Network : JNCCN 2015 Nov 13 11 1337-46
Pitfalls in RECIST Data Extraction for Clinical Trials: Beyond the Basics.
Abramson RG, McGhee CR, Lakomkin N, Arteaga CLAcademic radiology 2015 Jun 22 6 779-86
Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CLMolecular & cellular proteomics : MCP 2015 Jul 14 7 1959-76
Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CLCancer research 2015 Jan 75 2 405-14
Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts.
Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MCJournal of biomedical optics 2015 Feb 20 2 26004
Utility of [18?F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.
Whisenant JG, McIntyre JO, Peterson TE, Kang H, Sánchez V, Manning HC, Arteaga CL, Yankeelov TEMolecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging 2015 Feb 17 1 119-28
Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJCirculation 2015 Dec 132 23 2248-58
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).
Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, Dees EC, Richardson AL, Nanda R, Rimawi MF, Ryabin N, Najita JS, Barry WT, Arteaga CL, Wolff AC, Krop IE, Winer EP, Van den Abbeele ADJournal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Aug 33 24 2623-31
Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes.
Ju JH, Oh S, Lee KM, Yang W, Nam KS, Moon HG, Noh DY, Kim CG, Park G, Park JB, Lee T, Arteaga CL, Shin ICell death and differentiation 2015 Apr 22 4 665-76
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Liu S, Meng X, Chen H, Liu W, Miller T, Murph M, Lu Y, Zhang F, Gagea M, Arteaga CL, Mills GB, Meric-Bernstam F, González-Angulo AMOncotarget 2014 Oct 5 19 9049-64
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.
Arteaga CL, Engelman JACancer cell 2014 Mar 25 3 282-303
Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
Abramson VG, Cooper Lloyd M, Ballinger T, Sanders ME, Du L, Lai D, Su Z, Mayer I, Levy M, LaFrance DR, Vnencak-Jones CL, Shyr Y, Dahlman KB, Pao W, Arteaga CLBreast cancer research and treatment 2014 Jun 145 2 389-99
Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.
Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao WThe oncologist 2014 Jun 19 6 616-22
Evaluating HER2 amplification status and acquired drug resistance in breast cancer cells using Raman spectroscopy.
Bi X, Rexer B, Arteaga CL, Guo M, Mahadevan-Jansen AJournal of biomedical optics 2014 Feb 19 2 025001
PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HLHematology/oncology and stem cell therapy 2014 Dec 7 4 142-8
Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer.
Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CLCancer research 2013 Oct 73 20 6346-58
An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SACancer research 2013 Oct 73 19 6024-35
Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110a inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.
Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CLCancer research 2013 Oct 73 19 6013-23
Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CLClinical cancer research : an official journal of the American Association for Cancer Research 2013 Oct 19 19 5390-401
The genomic map of breast cancer: which roads lead to better targeted therapies?
Balko JM, Stricker TP, Arteaga CLBreast cancer research : BCR 2013 15 4 209
Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM, Kuba MG, Miller TW, Davies BR, Arteaga CLBreast cancer research : BCR 2013 15 4 R55
- Neratinib: Inching up on the cure rate of HER2+ breast cancer?
- Advanced, Inflammatory, Metastatic or Recurrent Breast Cancers
- Breast Cancers
- Medical Treatment of Breast Cancer
Q&A by Carlos Arteaga, M.D.
Articles by Dr. Arteaga
Showing 1 locations